𝔖 Bobbio Scriptorium
✦   LIBER   ✦

DOP074 Adalimumab monotherapy versus combination therapy with adalimumab and immunomodulators for Crohn's disease: A meta-analysis

✍ Scribed by Kopylov, U.; Al-Taweel, T.; Yaghoobi, M.; Afif, W.; Bitton, A.; Lakatos, P.L.; Ben-Horin, S.; Seidman, E.G.

Book ID
122321346
Publisher
Oxford University Press
Year
2014
Tongue
English
Weight
161 KB
Volume
8
Category
Article
ISSN
1873-9946

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Risk–benefit analysis of adalimumab vers
Risk–benefit analysis of adalimumab versus traditional non-biologic therapies for patients with Crohn's disease
✍ Edward V. Loftus Jr; Scott J. Johnson; Si-Tien Wang; Eric Wu; Parvez M. Mulani; πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 474 KB πŸ‘ 1 views

Background: Adalimumab is indicated for the treatment of moderately to severely active Crohn's disease (CD). A systematic analysis of risks and benefits of adalimumab versus traditional non-biologic therapies for patients refractory to non-biologic therapy is lacking. Methods: A base-case analysis